Joint position statement: 87.5% of National Psoriasis Foundation and International Psoriasis Council members agreed routine latent TB testing is not required for psoriasis patients on IL-17 or IL-23 inhibitors, with exceptions (concomitant immunosuppression, TB-endemic areas).
Guideline
Blauvelt et al. Joint position statement from the National Psoriasis Foundation Medical Board and the International Psoriasis Council on routine testing for latent tuberculosis infection prior to and during treatment of psoriasis patients with interleukin 17 or interleukin 23 inhibitors